These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 16838646

  • 1. [Chronic myelogenous leukemia].
    Urabe A.
    Nihon Rinsho; 2006 Jul; 64(7):1286-90. PubMed ID: 16838646
    [Abstract] [Full Text] [Related]

  • 2. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 3. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N.
    Gan To Kagaku Ryoho; 2005 Mar 15; 32(3):297-303. PubMed ID: 15791812
    [Abstract] [Full Text] [Related]

  • 4. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

  • 5. [Treatment strategies for chronic myeloid leukemia].
    Jinnai I.
    Rinsho Ketsueki; 2005 Jan 01; 46(1):1-6. PubMed ID: 16708910
    [No Abstract] [Full Text] [Related]

  • 6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group.
    N Engl J Med; 2003 Oct 09; 349(15):1423-32. PubMed ID: 14534335
    [Abstract] [Full Text] [Related]

  • 7. [Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
    Turhan AG.
    Bull Cancer; 2005 Jan 09; 92(1):75-82. PubMed ID: 15689327
    [Abstract] [Full Text] [Related]

  • 8. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators.
    N Engl J Med; 2003 Mar 13; 348(11):994-1004. PubMed ID: 12637609
    [Abstract] [Full Text] [Related]

  • 9. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
    Ajima A, Takayama N, Hasegawa Y, Kojima H, Nagasawa T.
    Gan To Kagaku Ryoho; 2003 Nov 13; 30(12):1997-9. PubMed ID: 14650975
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA.
    Cancer; 2004 Dec 01; 101(11):2574-83. PubMed ID: 15493042
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 14. [Recent progress in therapy for chronic myelogenous leukemia].
    Urabe A.
    Gan To Kagaku Ryoho; 1997 Jul 01; 24(9):1066-73. PubMed ID: 9239158
    [Abstract] [Full Text] [Related]

  • 15. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.
    Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833
    [Abstract] [Full Text] [Related]

  • 16. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N.
    Rinsho Byori; 2004 Feb 15; 52(2):136-44. PubMed ID: 15027317
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG, Deininger MW.
    Semin Hematol; 2003 Apr 15; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [Abstract] [Full Text] [Related]

  • 19. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Johnson JR, Bross P, Cohen M, Rothmann M, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R.
    Clin Cancer Res; 2003 Jun 15; 9(6):1972-9. PubMed ID: 12796358
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K.
    Cancer; 2007 Aug 15; 110(4):801-8. PubMed ID: 17607681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.